IP Library Granted Patent US 12,226,532
Granted Patent B2
US 12,226,532 · App. 17/072,625 · Granted Feb 18, 2025

Coated biological composition

Inventors: Timothy Ganey (Tampa, FL); Tracy Scott Anderson (Atlanta, GA)
Assignee: VIVEX BIOLOGICS GROUP, INC.
A61K9/5031A61K9/5123A61L27/3608A61L27/3804C12N5/0663A61L2430/38C07C31/225C07C317/04C07H3/04C09D177/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,532
App. No.
17/072,625
Granted
Feb 18, 2025
Kind
B2
Abstract

A coated biological composition has a mixture of biologic material and a volume of a liquid protectant. The mixture of biologic material has non-whole cellular components or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of a liquid protectant is intermixed with the mixture of biologic material, wherein the liquid protectant forms a coating externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material, to form the coated biological composition. The coated biological composition is frozen and thereafter thawed and then frozen a second time for storage or frozen at least once and thawed and stored under refrigeration above freezing, or frozen and thawed and then concentrated by drying, or while frozen without thawing lyophilized for ambient or room temperature storage.

Claims (63)

1. A method of making a coated biological composition comprising the steps of:

(a) grinding a cut vertebral body to produce a mixture comprising crushed vertebral bone and bone marrow, wherein the cut vertebral body is obtained from a cadaver donor;

(b) mechanically separating cellular and non-cellular components of the bone marrow from the vertebral bone in the mixture by tumbling and sieving the vertebral bone from a decanted fluid of the bone marrow comprising the cellular components comprising whole cells, and non-whole cellular components comprising non-whole cell components;

(c) concentrating the decanted fluid by centrifugation;

(d) filtering the decanted fluid through a blood filter to form a mixture including the cellular and non-whole cellular components and remove any remaining vertebral bone;

(e) separating the cellular components comprising whole cells and non-whole cellular components of the bone marrow directly from the mixture of step (d) by density gradient centrifugation, wherein the separation under centrifugation establishes a cell density gradient;

(e) collecting non-cellular fractions or non-cellular components or combinations-thereof of predetermined density from the gradient;

(f) washing the non-cellular fractions or non-cellular components or combinations thereof to create a mixture;

(g) suspending the mixture of step (f) to a predetermined concentration in a liquid protectant to form the coated biological composition;

(h) freezing the coated biological composition at a predetermined controlled rate; and

(i) thawing and freezing the coated biological composition a second time prior to storage;

(ii) thawing and refrigerating the coated biological composition;

(iii) thawing and concentrating the coated biological composition by drying; or

(iv) lyophilizing the frozen coated biological composition for ambient or room temperature storage.

2. The method of claim 1 , wherein the liquid protectant is a polyampholyte protectant or polyampholyte cryoprotectant, a glycerol-based protectant, dimethyl sulfoxide (DMSO), a glycol, trehalose, a molecular hydrogel preservative, sucrose or a dextrose based protectant.

3. The method of claim 1 , further comprising adding a volume of cartilage particles, wherein the particles are intermixed with the coated biological composition and coated with the liquid protectant.

4. The method of claim 1 , further comprising adding a volume of nucleus pulposus particles, wherein the particles are intermixed with the coated biological composition and coated with the liquid protectant.

5. The method of claim 1 , further comprising adding a volume of bone particles, wherein the particles are intermixed with the coated biological composition and coated with the liquid protectant.

6. The method of claim 5 wherein the coated biological composition is freeze dried or hypothermic dehydrated.

7. The method of claim 6 wherein the dried coated biological composition is micronized into particles of 1000 microns or less.

8. The method of claim 6 wherein the dried coated biological composition is micronized into particles of 400 microns or less.

9. The method of claim 5 wherein the bone particles include a mixture of cortical bone particles and cancellous bone particles.

10. The method of claim 1 , further comprising:

diluting the coated biological composition in saline without spinning;

and implanting the diluted mixture by packing, injection, or any other suitable means into a patient.

11. The method of claim 10 wherein the step of diluting the mixture includes warming the mixture at a temperature of 37 degrees C. for 2 to 3 minutes in a warm water bath.

12. The method of claim 1 wherein the thawed coated biological composition is re-frozen for storage prior to use.

13. The method of claim 1 wherein the thawed coated biological composition is refrigerated above freezing for storage prior to use.

14. The method of claim 1 wherein the thawed coated composition is processed to be stored at room temperature for storage.

15. The method of claim 1 wherein the thawed coated biological composition is concentrated by drying prior to being stored at room temperature to form a dried coated biological composition.

16. The method of claim 15 wherein the dried coated biological composition has a moisture content of 5% or less.

17. The method of claim 16 wherein an initial volume of the liquid protectant when reduced to a solid for drying or freeze-drying yields 5% or less of the initial volume.

18. The method of claim 17 wherein the dried coated biological composition when reconstituted in a liquid is suitable for direct implantation.

19. The method of claim 17 wherein the liquid protectant is a cryoprotectant.

20. The method of claim 1 wherein the liquid protectant is a polyampholyte protectant or polyampholyte cryoprotectant.

21. The method of claim 1 wherein the liquid protectant is dimethyl sulfoxide (DMSO).

22. The method of claim 1 , further comprising:

collecting whole cells from the cellular components of the bone marrow; and

adding the whole cells to the mixture suspended in the liquid protectant, wherein the liquid protectant coats the whole cells, and the coating deters attachment of the whole cells to the non-cellular fractions or non-cellular components or combinations thereof for a predetermined time.

23. The method of claim 22 wherein the coating retards or reduces premature differentiation of the whole cells of the mixture.

24. The method of claim 22 wherein the coating forms a spherical shrouding shell about each whole cell.

25. The method of claim 1 , wherein the coating buffers inflammation in a subject after implantation of the coated biological composition.

26. The method of claim 1 wherein the coating sustains regenerative potential and biologic function of the mixture during preservation and implantation.

27. The method of claim 1 further comprising:

implanting the coated biological composition in a patient; wherein the coating forms a shell which is configured to be metabolized by host cells of the patient after implantation after a predetermined time of three or more days.

28. The method of claim 27 wherein the predetermined time is up to six days.

29. The method of claim 1 wherein the non-cellular components derived from bone marrow further includes a select number of non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, and lipid rafts.

30. The method of claim 29 , further comprising:

implanting the coated biological composition in a patient having host cells; wherein

the combination of non-whole cell components with a select number of the non-whole cell fractions sustains pluripotency in the host cells.

31. The method of claim 30 wherein the select number of the non-whole cell fractions sustains pluripotency in the host cells including differentiated committed cells and non-differentiated and non-committed cells.

32. The method of claim 1 wherein the biological composition extends regenerative resonance that compliments or mimics tissue complexity.

33. The method of claim 1 , wherein the protectant creates a physical, electrical, or chemical gradient or combination thereof for tissue regeneration.

34. The method of claim 1 , wherein the step of freezing the suspended mixture at a predetermined controlled rate or freezing the coated biological composition a second time comprises cryopreservation of the mixture.

35. The method of claim 34 wherein the composition is maintained at ambient temperature prior to freeze drying.

36. The method of claim 34 , wherein cryopreservation occurs at a temperature that is sub-freezing.

37. The method of claim 36 wherein the cryopreservation temperature is from 0 degrees C. to −200 degrees C.

38. The method of claim 1 wherein the mixture of step (f) includes organelle fragments.

39. The method of claim 1 , wherein the mixture of step (f) is intermixed with a liquid protectant of a polyampholyte protectant for direct implantation, wherein said protectant is a 1-50 w/w % aqueous solution of at least one polyamine polymer compound comprising at least one polymer of units having side-chain amino groups, said at least one polymer of units being selected from a group consisting of ε-poly-L-lysine, a-poly-L-lysine, a poly-arginine, an allylamine polymer, and a partially methoxy-carbonylated allylamine polymer.

40. The method of claim 39 , wherein said liquid protectant is obtained by dissolving the at least one polyamine polymer compound in a physiological solution.

41. The method of claim 39 , wherein the physiological solution is a saline, Dulbecco-modified eagle MEM culture medium (DMEM), or a culture medium for cells or tissues.

42. The method of claim 39 , wherein said at least one polymer compound is €-poly-L-lysine having number-average molecular weight in a range of 1000-20,000.

43. The method of claim 39 , wherein remaining side-chain amino groups or remaining side-chain and terminal amino groups of the at least one polymer compound are not blocked by covalent bonding.

Assignments (4)
SECURITY INTEREST Recorded Aug 4, 2022
From: VIVEX BIOLOGICS GROUP, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 061084/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2020
From: GANEY, TIMOTHY; ANDERSON, TRACY SCOTT
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 054251/0511 →
CHANGE OF NAME Recorded Nov 3, 2020
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC
Reel/Frame 054281/0423 →
CHANGE OF NAME Recorded Nov 3, 2020
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 054281/0430 →
Continuity (14)
Division 15898558 · Feb 17, 2018
Continuation In Part 15837694 · Dec 11, 2017
Continuation In Part 15591513 · May 10, 2017
Continuation In Part 15590444 · May 9, 2017
Continuation In Part 15590475 · May 9, 2017
Continuation In Part 15591513 · May 10, 2017
Division 14683221 · Apr 10, 2015
Continuation In Part 15590444 · May 9, 2017
Division 14682523 · Apr 9, 2015
Continuation In Part 15590475 · May 9, 2017
Division 14682523 · Apr 9, 2015
Provisional Application 62129351 · Mar 6, 2015
Provisional Application 62129337 · Mar 6, 2015
Related Publication 20210030688A1 · Feb 4, 2021
References Cited (49)
US 2622027A · Torr · 1952 [cited by applicant]
US 5837539A · Caplan et al. · 1998 [cited by applicant]
US 9192695B2 · Shi · 2015 [cited by applicant]
US 9603355B2 · Matsumura et al. · 2017 [cited by applicant]
US 9675643B2 · Weston et al. · 2017 [cited by applicant]
US 9687511B2 · Weston et al. · 2017 [cited by applicant]
US 20030069639A1 · Sander · 2003 [cited by applicant]
US 20040097612A1 · Rosenberg et al. · 2004 [cited by applicant]
US 20050013872A1 · Freyman · 2005 [cited by applicant]
US 20070191963A1 · Winterbottom et al. · 2007 [cited by applicant]
US 20080014179A1 · Ferree · 2008 [cited by applicant]
US 20080268429A1 · Pietrzkowski · 2008 [cited by applicant]
US 20100105132A1 · Totey et al. · 2010 [cited by applicant]
US 20110172315A1 · Matsumura et al. · 2011 [cited by applicant]
US 20120053692A1 · Voor et al. · 2012 [cited by applicant]
US 20130059782A1 · Murat et al. · 2013 [cited by applicant]
US 20130071358A1 · Peterson · 2013 [cited by applicant]
US 20140065240A1 · Mitsialis · 2014 [cited by applicant]
US 20140212949A1 · Kim · 2014 [cited by examiner]
US 20150132266A1 · Schiller et al. · 2015 [cited by applicant]
US 20160015753A1 · Temple · 2016 [cited by applicant]
US 20160030639A1 · Shi · 2016 [cited by applicant]
US 20160256490A1 · Weston et al. · 2016 [cited by applicant]
WO 2014159662 · 2014 [cited by applicant]
WO 2015016761 · 2015 [cited by applicant]
Merriam-Webster, Extant definition, retreived from the internet 03242023: https://www.merriam-webster.com/dictionary/extant (Year : 2023). [cited by examiner]
Collins Dictionary, Metabolome definition, retrieved from the internet: https://www.collinsdictionary.com/us/dictionary/english/metabolome (Year: 2023). [cited by examiner]
ATCC Thawing, Propagating and Cryopreserving Protocol for NCI-PBCF-CRL, A-375 Malignant melanoma cells, Sep. 12, 2013 (Year: 2013). [cited by examiner]
Lorincz et al., Journal of Extracellular Vesicles, 2014, pp. 1-8 (Year: 2014). [cited by examiner]
Linetsky et al., CellR4 2013; 1(3): e577, 15 pages (Year: 2013). [cited by examiner]
Bone Structure and Function; ASBMR educational materials; https:/depts.washington.edu/bonebio/ASBMRed/structure.html. [cited by applicant]
Cells and Organelles; http://biology.cld.uc.edu/courses/bio104/cells.htm. [cited by applicant]
Derivative definition; Merriam Webster; http://www.merriam-webster.com/dictionary/derivative. [cited by applicant]
E.Linetsky, N.Kenyon, H.Li, X.Xu and C.Ricordi; Increased Immunogenicity of Human Vertebral Body Marrow After Processing in Bovine Versus Human Serum Albumin; Elsevier Science Inc.; Transplantation Proceedings 29, 1960 … [cited by applicant]
Matsumura, Kazuaki; Hyon, Suong-Hyu; Polampholytes as low toxic efficient cryoprotective agents with antifreeze protein properties; Biomaterials 30, 2009, 4842-4849. [cited by applicant]
Nottestad, Sheri Y.; Baumel, Julian J.; Kimmel, Donald B.; Recker, Robert R. and Heany, Robert P; The Proportion of Trabecular Bone in Human Vertebrae; Journal of Bone and Mineral Research, vol. 2, No. 3 1987. [cited by applicant]
Oryan et al; Bone regenerative medicine: classic options, novel strategies, and future directions, Journal of Orthopaedic Surgery and Research, 2014, vol. 9:18, pp. 1-27. [cited by applicant]
Brockbank et al., Advances in Biopreservation, 2006, pp. 157-196; retrieved from the internet; www.andrew.cmu.edu/user/yr25/TaylorPublications/MJTaylor108.pdf. [cited by applicant]
Liu et al., Nanoscale, 2017, vol. 9, pp. 4430-4438 (Year: 2017). [cited by applicant]
Nishimura et al Spine, 1998, vol. 23, Issue 14, pp. 1531-1538 (Year: 1998). [cited by applicant]
Matsumura et al., Journal of Biomaterials Science, Polymer Edition, 2013, vol. 24, No. 12, pp. 1484-1497 (Year: 2013). [cited by applicant]
Matsumura et al., Cell Transplantation, vol. 19, pp. 691-699, 2010 (Year: 2010). [cited by applicant]
Weston et al., BioDrugs (2019) 33: 137-158 (Year: 2019). [cited by applicant]
U.S. Appl. No. 15/590,444, “Final Office Action,” Dec. 21, 2023, 15 pages. [cited by applicant]
U.S. Appl. No. 15/898,558, “Non-Final Office Action,” Feb. 23, 2024, 26 pages. [cited by applicant]
Hiraki et al., “Use of ADME Studies to Confirm the Safety of E-polylysine as a Preservative in Food,” Regulatory Toxicology and Pharmacology, vol. 37, No. 2, 2003, pp. 328-340. [cited by applicant]
Shi et al., “Antimicrobial, Antioxidant, and Antitumor Activity of Epsilon-poly-l-lysine and Citral, Alone or in Combination,” Food & Nutrition Research, vol. 60, No. 31891, 2016, 8 pages. [cited by applicant]
Williams et al., “Mesenchymal Stem Cells: Biology, Pathophysiology, Translational Findings, and Therapeutic Implications for Cardiac Disease,” Circulation Research, 2011, vol. 109, pp. 923-940. [cited by applicant]
U.S. Appl. No. 15/898,558, “Final Office Action”, mailed Oct. 7, 2024, 28 pages. [cited by applicant]